Skip to main content

news

Shardul Amarchand Mangaldas & Co (SAM) has advised private equity major Advent International on the purchase of a 50.1 percent stake in India’s Suven Pharmaceuticals, with Cyril Amarchand Mangaldas (CAM) advising the sellers, the Jasti family.

According to Reuters, Advent is expected to make an additional open offer for up to 26 percent of the voting share capital held by public shareholders. Advent intends to explore merging Suven with its wholly owned Cohance Lifesciences to build a company that specializes in active pharmaceutical ingredients as well as contract development and manufacturing businesses, Reuters added.

 

The CAM team was led by partner Shishir Vayttaden, with support from partners Namrata Kolar, Biplab Lenin, and Avaantika Kakkar.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Cleary, A&O Shearman advise on Goodyear's $701 mln Dunlop sale

by Asian Legal Business《亚洲法律杂志》 |

Cleary Gottlieb has advised tyremaker Goodyear Tire & Rubber Company on the $701 million sale of its Dunlop brand to Japan's Sumitomo Rubber Industries (SRI), which was represented by A&O Shearman.

Deals

Mori Hamada, Nagashima Ohno advise on $1.6 bln bid for Fujitsu General

by Asian Legal Business《亚洲法律杂志》 |

Japanese law firms Mori Hamada & Matsumoto and Nagashima Ohno & Tsunematsu are playing key roles in Paloma Rheem Holdings' 257 billion yen ($1.6 billion) offer to acquire air conditioner manufacturer Fujitsu General.

Deals

CAM, Khaitan, Linklaters act on $355 mln Sai Life Sciences IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas has driven the $355 million initial public offering of TPG-backed Indian healthcare R&D firm Sai Life Sciences, with Khaitan & Co and Linklaters advising the bookrunning lead managers. CAM has also acted for selling promoter shareholders Sai Quest Syn.